Home » Stocks » CATB

Catabasis Pharmaceuticals, Inc. (CATB)

Stock Price: $1.93 USD -0.16 (-7.66%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $1.98 +0.05 (2.59%) Dec 3, 7:45 PM

Stock Price Chart

Key Info

Market Cap 38.76M
Revenue (ttm) n/a
Net Income (ttm) -34.93M
Shares Out 19.42M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $1.93
Previous Close $2.09
Change ($) -0.16
Change (%) -7.66%
Day's Open 2.15
Day's Range 1.85 - 2.16
Day's Volume 13,933,014
52-Week Range 1.32 - 8.20

More Stats

Market Cap 38.76M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.42M
Float n/a
EPS (basic) -2.14
EPS (diluted) -2.14
FCF / Share -1.66
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 444,224
Short Ratio 0.19
Short % of Float n/a
Beta 2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.66
Revenue n/a
Operating Income -35.21M
Net Income -34.93M
Free Cash Flow -32.23M
Net Cash 51.65M
Net Cash / Share 2.57
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -43.71%
ROE -79.77%
ROIC -195.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$24.00*
Low
24.0
Current: $1.93
High
24.0
Target: 24.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue--0.50----
Gross Profit--0.50----
Operating Income-27.09-26.37-27.09-35.56-31.66-21.68-18.12
Net Income-26.29-25.87-27.36-36.06-32.63-21.88-18.12
Shares Outstanding11.205.052.171.620.800.040.04
Earnings Per Share-2.35-5.12-12.62-22.20-40.60-515.60-478.00
Operating Cash Flow-26.57-23.47-26.84-32.86-29.79-20.41-16.37
Capital Expenditures-0.010.37-0.03-0.41-0.42-0.23-0.04
Free Cash Flow-26.58-23.10-26.86-33.27-30.21-20.64-16.41
Cash & Equivalents36.2437.5716.4838.6462.8914.7830.59
Total Debt2.25-2.485.728.894.75-
Net Cash / Debt33.9937.5714.0032.9254.0010.0330.59
Assets41.7839.1717.9040.2164.1715.9631.00
Liabilities6.064.236.1111.1213.688.8783.19
Book Value35.7234.9411.7929.0950.49-73.05-52.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catabasis Pharmaceuticals, Inc.
Employees 27

Stock Information

Ticker Symbol CATB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CATB
IPO Date June 25, 2015

Description

Catabasis Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.